A Phase 2, Randomized, Open Label, Multiple-Dose, Comparator, Parallel-Group, Safety and Tolerance Study of Buprenorphine Sublingual Spray (0.5 mg TID) Versus Standard of Care Post-Operative Narcotic Therapy for the Treatment of Post-Operative Pain

Trial Profile

A Phase 2, Randomized, Open Label, Multiple-Dose, Comparator, Parallel-Group, Safety and Tolerance Study of Buprenorphine Sublingual Spray (0.5 mg TID) Versus Standard of Care Post-Operative Narcotic Therapy for the Treatment of Post-Operative Pain

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2018

At a glance

  • Drugs Buprenorphine (Primary) ; Morphine; Oxycodone
  • Indications Postoperative pain
  • Focus Adverse reactions
  • Sponsors INSYS Therapeutics, Inc
  • Most Recent Events

    • 27 Jul 2018 According to an INSYS Therapeutics media release, the FDA has issued a Complete Response Letter (CRL) regarding the NDA for buprenorphine sublingual spray. The CRL indicates that, although the clinical development program demonstrated all three proposed doses of the product candidate were statistically significantly different than placebo in providing pain relief, some of the data suggested potential safety concerns.
    • 22 May 2018 According to an INSYS Therapeutics, Inc media release, company confirmed that an expert panel convened by the U.S. Food and Drug Administration (FDA) voted not to recommend approval of the company's New Drug Application (NDA) for a buprenorphine sublingual spray as a treatment for moderate-to-severe acute pain.
    • 02 Jan 2018 Planned End Date changed from 28 Dec 2017 to 28 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top